Selection criteria for 3D conformal radiotherapy versus volumetric-modulated arc therapy in high-grade glioma based on normal tissue complication probability of brain

Satoshi Tanabe¹,*, Haruna Takahashi¹,2, Hirotake Saito¹, Atsushi Ohta¹, Toshimichi Nakano³, Ryuta Sasamoto⁴, Miki Shioi¹, Satoru Utsunomiya⁴, Eisuke Abe³, Motoki Kaidu³ and Hidefumi Aoyama³

¹Department of Radiation Oncology, Niigata University Medical and Dental Hospital, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510, Japan
²Department of Radiation Technology, Niigata City General Hospital, 463-7 Shumoku, Chuo-ku, Niigata 950-1197, Japan
³Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510, Japan
⁴Department of Radiological Technology, Niigata University Graduate School of Health Sciences, 2-746 Asahimachi-dori, Chuo-ku, Niigata 951-8122, Japan

*Corresponding author. Department of Radiation Oncology, Niigata University Medical and Dental Hospital, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510, Japan. Tel: +81-25-227-2315; Fax: +81-25-227-0788; Email: s-tanabe@med.niigata-u.ac.jp

(Received 30 July 2018; revised 20 October 2018; editorial decision 18 November 2018)

ABSTRACT

There are no quantitative selection criteria for identifying high-grade glioma (HGG) patients who are suited for volumetric-modulated arc therapy (VMAT). This study aimed to develop selection criteria that can be used for the selection of the optimal treatment modality in HGG. We analyzed 20 patients with HGG treated by 3D conformal radiotherapy (3DCRT). First, VMAT plans were created for each patient retrospectively. For each plan, the normal tissue complication probability (NTCP) for normal brain was calculated. We then divided the patients based on the NTCPs of the 3DCRT plans for normal brain, using the threshold of 5%. We compared the NTCPs of the two plans and the gross tumor volumes (GTVs) of the two groups. For the GTVs, we used receiver operating characteristic curves to identify the cut-off value for predicting NTCP < 5%. We determined the respective correlations between the GTV and the GTV’s largest cross-sectional diameter and largest cross-sectional area. In the NTCP ≥ 5% group, the NTCPs for the VMAT plans were significantly lower than those for the 3DCRT plans (P = 0.0011). The NTCP ≥ 5% group’s GTV was significantly larger than that of the NTCP < 5% group (P = 0.0016), and the cut-off value of the GTV was 130.5 cm³. The GTV was strongly correlated with the GTV’s largest cross-sectional diameter (R² = 0.82) and largest cross-sectional area (R² = 0.94), which produced the cut-off values of 7.5 cm and 41 cm², respectively. It was concluded that VMAT is more appropriate than 3DCRT in cases in which the GTV is ≥ 130.5 cm³.

Keywords: radiotherapy; high-grade glioma; VMAT; NTCP; selection criteria

INTRODUCTION

Post-operative radiotherapy is absolutely essential for high-grade glioma (HGG). With the technical advances in radiotherapy, the use of intensity-modulated radiation therapy (IMRT) and/or volumetric-modulated arc therapy (VMAT) for the radiation of HGGs is increasingly common as a substitute for 3D conformal radiotherapy (3DCRT) [1]. Several studies have reported that IMRT including VMAT can achieve high conformity for the target while reducing the dose to organs at risk (OARs), compared with 3DCRT [2–7]. Wagner et al. [2] described their dosimetric comparison of IMRT and 3DCRT plans for 14 consecutive patients with malignant glioma, and they reported that if the planning target
volume (PTV) is near an OAR, the PTV coverage for IMRT is more acceptable than that for 3DCRT. Lorentini et al. [3] assessed the clinical dosimetric scenario that could benefit the most from an IMRT plan versus a 3DCRT plan for 17 patients with glioblastoma, and they reported that the higher the number of PTV–OARs overlaps, the better the target coverage provided by IMRT compared with a 3DCRT plan. In particular, Sakanaka et al. [7] reported that VMAT could reduce the number of monitor units, while maintaining target coverage comparable with that of IMRT. However, it is difficult to use VMAT for all HGG patients, because it requires a longer preparation time and more human resources compared with 3DCRT.

Considering the ease of the preparation for 3DCRT, it has not till now been clear which patients would benefit from undergoing VMAT rather than 3DCRT. To our knowledge, there are no quantitative selection criteria for identifying HGG patients who are suited for VMAT. As HGG can grow rapidly, it is desirable to determine the treatment selection of radiotherapy as early as possible after surgery. In regard to this point, the gross tumor volume (GTV) can be identified on diagnostic images at the medical examination. Hence, we conducted the present study to develop quantitative selection criteria, focused on the GTV, that could be used for the selection of the optimal treatment modality in HGG, in a comparison of the VMAT plan with the 3DCRT plan.

**METHODS**

**Patients**

Among 46 consecutive HGG patients who underwent 3DCRT at our institution in the 18-month period from August 2014 to February 2016, those who met the following criteria were included: (i) the patients to whom 3DCRT of 60 Gy in 30 fractions was delivered, and (ii) enhancement of their tumor was observed on the T2-weighted or fluid-attenuated inversion recovery (FLAIR) MRI, and (iii) the tumor was not located in the brainstem. As a result, 20 patients were identified and considered suitable for the further analyses. The clinical characteristics of the 20 patients are summarized in Table 1. There were 12 males and eight females, with a median age of 59 years (range 29–72 years). The median GTV was 91.9 cm³ (range 14.0–391.5 cm³), and the median maximal diameter of the GTV was 7.3 cm (range 4.1–11.0 cm). This study was approved by our institutional review board (IRB) (No. 2015–2632). All patients were provided their informed consent under our IRB concerning the use of their data for research purpose.

**Table 1. Patient characteristics**

|               | n = 20 |
|---------------|-------|
| Sex           |       |
| Male          | 12    |
| Female        | 8     |
| Age           |       |
| Median        | 59    |
| Range         | 29–72 |
| WHO grade     |       |
| Grade III     | 8     |
| Grade IV      | 12    |
| Tumor location|       |
| Parietal lobe  | 2     |
| Temporal lobe | 3     |
| Frontal lobe  | 12    |
| Parietal–temporal | 2 |
| Cerebellum    | 1     |
| GTV (cm³)     |       |
| Median        | 91.9  |
| Range         | 14.0–391.5 |
| Largest cross-sectional diameter (cm) |       |
| Median        | 7.3   |
| Range         | 4.1–11.0 |
| Largest cross-sectional area (cm²) |       |
| Median        | 38.6  |
| Range         | 11.7–84.6 |
| Surgery       |       |
| Gross total resection | 9 |
| Sub-total resection | 7 |
| Partial resection | 3 |
| Biopsy        | 1     |

**Treatment planning simulation in 3DCRT**

A treatment planning simulation in 3DCRT was performed with a 16-slice CT scanner (Lightspeed RT, General Electric, Freiburg, Germany). Radiotherapy (RT) treatment planning was generated with an Eclipse™ ver. 11.0 treatment planning system (Varian Medical Systems, Palo Alto, CA). The dose calculation was performed using the Anisotropic Analytical Algorithm ver. 11.0 in the Eclipse system. The GTV included the residual enhancing tumor, the tumor removal cavity, and the hyper-intense regions on the T2-weighted or FLAIR MRI, according to the Radiation Therapy Oncology Group (RTOG) guidelines for target delineation of glioblastoma (Fig. 1) [8].

In the initial plan, a clinical target volume (CTV) was created by expanding the GTV by 15-mm isotropic margins. The PTV was created by expanding the CTV by 3-mm isotropic margins. We refer to
residual enhancing tumor and the tumor removal cavity. The boost) was created by adding 15-mm isotropic margins around the fractions in total.

doses delivered in the initial and the boost plans was 60 Gy in 30 fractions. The margin between the beam-144°, respectively. In the initial plan, 50 Gy in 25 fractions at the isocenter was delivered with two 6 MV opposing beams on a Novalis-TX system (Varian Medical Systems and BrainLAB, Feldkirchen, Germany). The gantry angles were set to 0°, 218°, and the -initial and the ends of the multileaf collimators (MLCs) on the beam’s-eye view was set to 2 mm.

In the boost plan after 50 Gy in 25 fractions, the CTV (CTV-boost) was created by expanding the CTV-boost by 3-mm isotropic margins; 10 Gy in five fractions or 14 Gy in seven fractions at the isocenter were delivered with two 6 MV opposing beams in order to spare the OARs for each patient. The sum of the radiation doses delivered in the initial and the boost plans was 60 Gy in 30 fractions in total.

**Figure 1. Treatment planning images.** (a) The hyper-intense regions on this FLAIR MRI image are outlined in green. (b) The enhanced residual tumor on this MRI image is outlined in yellow. (c) The removal cavity on this CT image is outlined in blue. (d) The GTV on this CT image is outlined in red.

the CTV and the PTV in the initial plan as the ‘CTV-initial’ and ‘PTV-initial’, respectively. In the initial plan, 50 Gy in 25 fractions at the isocenter was delivered with five 6 MV coplanar beams on a Novalis-TX system (Varian Medical Systems and BrainLAB, Feldkirchen, Germany). The gantry angles were set to 0°, 72°, 144°, 218° and 290°. In cases in which the GTV was adjacent to critical OARs such as the brainstem and optic nerves, the prescribed dose was reduced to 46 Gy in 23 fractions. The margin between the PTV-initial and the ends of the multileaf collimators (MLCs) on the beam’s-eye view was set to 2 mm.

In the boost plan after 50 Gy in 25 fractions, the CTV (CTV-boost) was created by adding 15-mm isotropic margins around the residual enhancing tumor and the tumor removal cavity. The PTV (PTV-boost) was created by expanding the CTV-boost by 3-mm isotropic margins; 10 Gy in five fractions or 14 Gy in seven fractions at the isocenter were delivered with two 6 MV opposing beams in order to spare the OARs for each patient. The sum of the radiation doses delivered in the initial and the boost plans was 60 Gy in 30 fractions in total.

**Treatment planning simulation in VMAT**

For all HGG patients who satisfied the inclusion criteria, we retrospectively generated one-arc 6 MV VMAT plans (gantry angle: 181° to 179°) by using the simultaneous integrated boost method. A collimator angle was set to 30° in order to minimize the tongue-and-groove effect. The prescribed doses were 60 Gy in 30 fractions for the PTV-boost and 50 Gy in 30 fractions for the PTV-initial. All plans were designed so that 50% of the PTV-boost received the prescription dose, at least 99% of each PTV received 90% of the prescription dose, and no more than 2% of the PTV received 107% of the prescription dose. All OARs were evaluated as the planning OAR volume (PRV) in this study. For all PRVs, the following constraints were used: optic chiasm D2% (dose delivered to 2% of the considered structure volume) < 50 Gy, eyes D2% < 45 Gy, optic nerves D2% < 50 Gy, brainstem D2% < 54 Gy, lens mean dose < 6 Gy, and internal ears mean dose < 45 Gy. All plans were approved prior to the conformity of the PTV and normal brain.

**Evaluation of the normal tissue complication probability of normal brain**

In this study, the normal brain was defined as the whole brain minus the GTV. We evaluated the normal tissue complication probability (NTCP) of normal brain by using the Lyman–Kutcher–Burman (LKB) model in Eqs. (1) and (2):

\[
NTCP = \frac{1}{\sqrt{2\pi}} \int_{-\infty}^{t} e^{-\frac{x^2}{2}} dx
\]

\[
t = \frac{D - TD_{50}}{m \times TD_{50}}
\]

where \(TD_{50}\) is the tolerance dose for a 50% complication probability for uniform doses to the organ, and \(m\) is a dimensionless parameter for determining the slope of the complication probability according to the dose curve [9].

For the uniform dose \(D\) in Eq. (2), we used the generalized equivalent uniform dose (gEUD), as shown in Eq. (3):

\[
gEUD = \left( \sum_{i=1}^{N} v_i D_i^n \right)^{\frac{1}{n}}
\]

where \(D_i\) is the dose for each bin in a differential dose–volume histogram (DVH), \(v_i\) is the volume in a specific dose bin \(i\), and \(N\) is the unequal fractional sub-volume. The ‘\(a\)’ value is a parameter equal to 1/\(n\), in which \(n\) represents the volume dependence of the complication probability [7]. We adopted the following parameters to evaluate the radiation-induced brain necrosis as an end point: \(TD_{50} = 60, m = 0.15, a = 4\) [10].

**Evaluation**

The percentage volume of the normal brain receiving at least 5–60 Gy (\(V_{5 Gy}\)–\(V_{60 Gy}\)), \(D_{2%}\), mean dose, gEUD and NTCP were obtained from DVHs for each patient in order to compare the 3DCRT and VMAT plans (60 Gy in 30 fractions). In addition to the normal brain, the DVHs of the PTV-boost and the PRVs for the brainstem, optic chiasm, optic nerve, eye and lens were analyzed. The PTV-boost was assessed by calculating the \(D_{2%}\), \(D_{50%}\), \(D_{95%}\), \(V_{2%}\), \(V_{5%}\), \(V_{95%}\), homogeneity index defined as \((D_{95%} - D_{2%})/D_{50%}\) and conformity index (CI). For the determination of the CI, we used the following formula:
where $TV$ is the target volume, $V_{RI}$ is the volume of the reference isodose, and $TV_{RI}$ is the target volume covered by the reference isodose [11]. In the present study, we defined the reference isodose as the 95% isodose. In clinical practice, the TDS/5 (the tolerance dose for a 5% risk of developing Grade 3 toxicities within 5 years) is frequently used, and we therefore consider the TDS/5 appropriate for setting the cut-off value of the NTCP as 5% [12]. We divided the patients into two groups based on the NTCP of normal brain in each 3DCRT plan by using the threshold of 5% (NTCP < 5% and NTCP ≥ 5% groups), and we then compared the NTCPs for the 3DCRT and VMAT plans between these two groups. We also compared the GTV between the groups. The correlations between the GTV and the largest cross-sectional diameter of the GTV and between the GTV and the largest cross-sectional area (largest cross-sectional diameter by the largest diameter perpendicular to it) of the GTV were evaluated in reference to Wen et al. (Fig. 2) [13].

### Statistical analysis

The Wilcoxon signed rank test was used for comparisons of 3DCRT and VMAT, and of the GTV for the NTCP < 5% and NTCP ≥ 5% groups. In order to evaluate the prediction accuracy of the GTV for NTCP < 5%, the area under the curve (AUC) of a receiver operating characteristic (ROC) curve was used. The best cut-off value for predicting NTCP < 5% of ROC curves was determined by the Youden’s index, defined as the point that (sensitivity + specificity – 1) becomes the maximum [14]. A $P$-value of <0.05 was considered statistically significant. All statistical analyses were performed using the JMP ver. 11 program (SAS, Cary, NC), R statistical software version 3.0.2 (the R Foundation for Statistical Computing, Vienna, Austria), and EZR (a graphical user interface for R, Saitama Medical Center, Jichi Medical University, Saitama, Japan).

### RESULTS

#### Dosimetric comparison between the 3DCRT and VMAT plans

Table 2 shows the results of the dosimetric comparison between the 3DCRT and VMAT plans. With respect to the PTV-boost, the median CI value in the VMAT plan (0.93) was significantly superior to that in the 3DCRT plan (0.59) ($P < 0.001$), although there were no significant differences between the 3DCRT and VMAT plans in the median values of $D_{90\%}$ (57.3 Gy vs 57.2 Gy, $P = 0.85$), $D_{98\%}$ (54.7 Gy vs 56.3 Gy, $P = 0.23$), $D_{2\%}$ (62.5 Gy vs 63.0 Gy, $P = 0.14$), $V_{90\%}$ (98.2% vs 99.7%, $P = 0.079$), $V_{95\%}$ (95.9% vs 95.7%, $P = 0.90$) and $HI$ (0.14 vs 0.11, $P = 0.33$), respectively.

There were no significant differences between the 3DCRT and VMAT plans in the median value of the gEUD (43.3 Gy vs 39.3 Gy, $P = 0.06$) or the NTCPs for normal brain (3.2% vs 1.1%, $P = 0.06$), respectively, on the whole. In contrast, in the NTCP ≥ 5% group, the NTCPs for the VMAT plans (4.0%) were significantly lower than the NTCPs for the 3DCRT plans (9.6%) ($P = 0.001$). The VMAT plan had clear advantages with respect to the differences between the $V_{SS\, Gy}$, $V_{60\, Gy}$, and $D_{2\%}$ for normal brain. There were no significant differences in the median value of the mean dose and $V_{SS\, Gy}$-$V_{50\, Gy}$ for normal brain and $D_{2\%}$ for each PRV in the 3DCRT or VMAT plans.

### Determination of the cut-off value of the GTV

The distribution of the GTV values between the NTCP < 5% group and the NTCP ≥ 5% group is illustrated in Fig. 3a. The median value of the GTV in the NTCP≥5% group (149.5 cm$^3$, range 45.4–391.5 cm$^3$) was significantly larger than that in the NTCP < 5% group (64.2 cm$^3$, range 14.0–246.4 cm$^3$) ($P = 0.0016$). As shown in Fig. 3b, the cut-off value of the GTV was 130.5 cm$^3$ (AUC 0.93, 95% CI 0.78–1.0).

---

**Fig. 2.** The largest cross-sectional diameter of the GTV and the largest diameter perpendicular to it. The GTV on this CT image is outlined in red.
Table 2. Comparison of dosimetric parameters for 3DCRT and VMAT plans

| Structure                  | 3D-CRT median (range) | VMAT median (range) | P-value |
|----------------------------|-----------------------|---------------------|---------|
| PTV-boost (60 Gy)          |                       |                     |         |
| $D_{95\%}$ (Gy)            | 57.3 (46.7–60.0)      | 57.2 (50.6–58.0)    | 0.85    |
| $D_{99\%}$ (Gy)            | 54.7 (45.4–59.8)      | 56.3 (49.4–57.5)    | 0.23    |
| $D_{2\%}$ (Gy)             | 62.5 (60.7–64.5)      | 63.0 (62.0–63.8)    | 0.14    |
| $V_{90\%}$ (%)             | 98.2 (73.7–100)       | 99.7 (82.7–100)     | 0.079   |
| $V_{95\%}$ (%)             | 95.9 (69.6–100)       | 95.7 (76.7–99.3)    | 0.90    |
| HI                         | 0.14 (0.026–0.29)     | 0.11 (0.085–0.24)   | 0.33    |
| CI                         | 0.59 (0.43–0.77)      | 0.93 (0.69–0.96)    | <0.001* |
| Normal brain               |                       |                     |         |
| $V_{5\text{ Gy}}$ (%)      | 94.1 (68.7–100)       | 94.5 (74.5–100)     | 0.97    |
| $V_{10\text{ Gy}}$ (%)     | 88.2 (59.0–99.8)      | 86.9 (64.3–99.8)    | 0.88    |
| $V_{15\text{ Gy}}$ (%)     | 82.0 (56.1–97.8)      | 74.6 (49.1–95.2)    | 0.48    |
| $V_{2\text{ Gy}}$ (%)      | 74.6 (45.9–96.0)      | 63.7 (36.2–87.1)    | 0.083   |
| $V_{25\text{ Gy}}$ (%)     | 63.0 (27.0–90.5)      | 51.2 (26.2–78.3)    | 0.33    |
| $V_{30\text{ Gy}}$ (%)     | 49.7 (20.4–77.5)      | 41.1 (19.2–67.6)    | 0.28    |
| $V_{35\text{ Gy}}$ (%)     | 43.4 (16.7–67.4)      | 33.5 (14.7–55.9)    | 0.19    |
| $V_{40\text{ Gy}}$ (%)     | 37.5 (13.5–58.1)      | 27.8 (11.9–46.1)    | 0.14    |
| $V_{45\text{ Gy}}$ (%)     | 32.6 (11.3–50.5)      | 23.7 (9.88–39.5)    | 0.15    |
| $V_{50\text{ Gy}}$ (%)     | 24.2 (6.74–43.6)      | 16.7 (7.58–31.9)    | 0.14    |
| $V_{55\text{ Gy}}$ (%)     | 18.9 (5.20–37.1)      | 10.9 (3.85–20.9)    | 0.0032* |
| $V_{60\text{ Gy}}$ (%)     | 10.3 (1.87–24.9)      | 4.94 (1.14–7.47)    | <0.001* |
| $D_{2\%}$ (%)              | 62.1 (59.9–63.9)      | 61.3 (59.2–62.1)    | 0.0068* |
| Mean dose (Gy)             | 31.6 (20.2–43.9)      | 27.7 (19.1–38.8)    | 0.26    |
| gEUD                       | 43.3 (34.3–49.9)      | 39.3 (33.3–45.9)    | 0.06    |
| NTCP (%)                   | 3.2 (0.21–13.2)       | 1.1 (0.15–5.81)     | 0.06    |
| <5                         | 1.2 (0.21–4.67)       | 0.8 (0.15–3.02)     | 0.09    |
| ≥5                         | 9.6 (5.40–13.2)       | 4.0 (2.80–5.81)     | 0.0011* |
| Brainstem_PRV              |                       |                     |         |
| $D_{2\%}$ (Gy)             | 47.5 (30.4–57.4)      | 49.8 (27.0–53.8)    | 0.67    |
| Optic chiasm_PRV           |                       |                     |         |
| $D_{2\%}$ (Gy)             | 46.6 (5.16–54.5)      | 48.5 (6.07–49.9)    | 0.17    |
| Optic nerve_PRV            |                       |                     |         |
| $D_{2\%}$ (Gy)             | 45.8 (2.86–54.4)      | 46.2 (2.77–49.8)    | 0.17    |

Continued
Figure 4 shows the relationship between the GTV and the largest cross-sectional diameter of the GTV (Fig. 4a) and the largest cross-sectional area of the GTV (Fig. 4b). The GTV was strongly correlated with both the largest cross-sectional diameter of the GTV ($R^2 = 0.82$) and the largest cross-sectional area ($R^2 = 0.94$), which produced the cut-off values of 7.5 cm and 41 cm$^2$.

**DISCUSSION**

Our analyses revealed two important findings. First, the high NTCP of normal tissue is associated with a large GTV. Second, compared with 3DCRT, the use of VMAT can significantly reduce the NTCP of normal brain for plans with a high NTCP. These findings can form the basis of concise and objective selection criteria for radiotherapy techniques in HGG patients.

Table 2. Continued

| Structure         | 3D-CRT median (range) | VMAT median (range) | $P$-value |
|-------------------|-----------------------|---------------------|-----------|
| Eye_PRV           |                       |                     |           |
| $D_{2\%}$ (Gy)    | 21.2 (1.29–46.6)      | 21.3 (1.29–40.3)    | 0.86      |
| Lens_PRV          |                       |                     |           |
| Mean dose (Gy)    | 2.6 (0.70–6.08)       | 3.2 (0.0–5.64)      | 0.43      |

$D_{\%}$ = the radiation dose delivered to $\%$ of the structure, $V_{\%}$ = the percentage of the volume of the structure that receives $\geq \%$ of the prescribed dose, HI = homogeneity index, CI = conformity index, gEUD = generalized equivalent uniform dose, NTCP = normal tissue complication probability.
The NTCP is calculated to estimate the risk of normal tissue complications based on the dose distribution. It is expressed as an approximation formula of the cumulative normal distribution of dose and volume histograms. The integrated parameters vary depending on each organ and complication. In the LKB model, the dose distribution is transformed into the generalized equivalent uniform dose (gEUD), and the gEUD is then used to calculate the NTCP.

Our present findings demonstrated that the NTCP value for normal brain can be significantly decreased by the use of VMAT in the NTCP ≥ 5% group, although no significant difference was found in the NTCP < 5% group. Thus, in terms of radiation-induced brain necrosis, VMAT has few advantages over 3DCRT in patients with an NTCP value < 5%. Considering the preparatory period for radiotherapy and the human resources required, the selection of 3DCRT can be justified.

In clinical practice, the choice of the radiotherapy technique is usually made as part of the outpatient service. However, it is impossible to evaluate the NTCP for normal brain at that stage. In this study, we observed the patient’s GTV values and identified the GTV that produced the cut-off value of 5% NTCP, based on our hypothesis that this could be a decisive criterion for the selection between 3DCRT and VMAT. As shown in Fig. 4, the GTV was strongly correlated with the largest cross-sectional diameter of the GTV \( R^2 = 0.82 \) and the largest cross-sectional area \( R^2 = 0.94 \). Our proposed cut-off value is useful in that the choice between 3DCRT and VMAT can thus be made based on the CT images acquired for treatment planning, because these parameters are easily assessed in the diagnostic MRI images.

Several studies have reported that intensity-modulated radiotherapy (IMRT) including VMAT is superior to 3DCRT in radiotherapy for HGG [2–7]. As mentioned in the Introduction section, Lorentini et al. [2] reported that the higher the number of PTV–OARs overlaps, the better the target coverage provided by IMRT compared with a 3DCRT plan. However, their study did not take the volume of the PTV–OAR overlap into account. Moreover, a treatment planning system was needed in order to measure the volume of the overlap in that study. Thus, the use of these methods might be difficult in the first medical examination, because there is no quantitative information about treatment planning. In contrast, in the present study, we assessed the selection criteria for VMAT using the NTCP for normal brain as a quantitative index prior to the treatment planning process.

In a similar study by MacDonald et al. [4], IMRT significantly lowered the NTCP for normal brain from 0.23% with 3DCRT to 0.043% \( P = 0.003 \). The lower NTCP values in the MacDonald study compared with those in the present study are due to the difference in the definition of normal brain (defined as brain minus PTV in the MacDonald study). The study by Hermanto et al. [5] evaluated the normal brain defined as two different volumes: brain minus PTV and brain minus GTV, assessing the integral dose to normal brain for 20 HGG patients. Although more research comparing the actual occurrence rate for brain necrosis and NTCP is necessary in order to precisely evaluate the risk of radiation-induced brain necrosis, it is reasonable to propose that ‘brain minus GTV’ is preferable to ‘brain minus PTV’ because the set-up margin differs between institutions. We eventually identified ‘the largest cross-sectional diameter of the GTV’ and/or ‘the largest cross-sectional area of the GTV’ on the diagnostic images as the selection criteria for VMAT. Therefore, our proposed criteria are clinically relevant because each value can be easily obtained by measuring it on the diagnostic imaging at an outpatient service.

There have been no randomized controlled trials comparing the clinical outcomes of IMRT with those of 3DCRT in HGG. In prostate or head and neck cancers, the results of dosimetric studies correlate with the incidence of actual adverse events [15, 16]. In HGG patients, it is feasible to consider the application of IMRT based on the findings from radiotherapy simulation studies. Our present findings may be useful for building the theoretical basis for future prospective clinical trials.

Our study has limitations that are inherent in simulation studies. First, we adopted only the LKB model in order to evaluate the NTCP, which is largely influenced by the extrapolated parameters. However, the parameters we adopted for the LKB model are also used in many studies, and this type of vulnerability might be encountered in other studies relevant to NTCP. Second, we did not investigate the influence of the GTV location. In cases in which the GTV is smaller than that in the criteria proposed herein, and in cases in which the GTV is adjacent to critical OARs, the use of VMAT may be more effective compared with 3DCRT. Third, we did not consider the fraction schemes, and no correction for fractions were applied in order to compare the NTCP between 3DCRT and VMAT plans. Therefore, our proposed cut-off value should be regarded as only part of the basis for decision-making in clinical settings.

CONCLUSION

We developed quantitative selection criteria for VMAT in HGG in terms of radiation-induced brain necrosis. Our findings show that VMAT is more appropriate than 3DCRT in cases in which the GTV is ≥130.5 cm\(^3\), which corresponds to the threshold of 7.5 cm in the largest cross-sectional diameter of the GTV and to 41 cm\(^2\) in the largest cross-sectional area of the GTV on diagnostic images.

ACKNOWLEDGEMENTS

Some of the results of the present study were presented at the 26th Annual Meeting of the Japanese Society of Stereotactic Radiosurgery in June 2017 (Osaka, Japan), at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in September 2017 (San Diego, CA), and at the 30th Annual Meeting of the Japanese Society for Radiation Oncology (JASTRO) in November 2017 (Osaka, Japan).

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.

FUNDING

Part of the present study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science [Grant Nos 15H04903 and 18K15584].
REFERENCES
1. Wang M, Ma H, Wang X et al. Integration of BOLD-fMRI and DTI into radiation treatment planning for high-grade gliomas located near the primary motor cortexes and corticospinal tracts. *Radiat Oncol* 2015;10:64.
2. Wagner D, Christiansen H, Wolff H et al. Radiotherapy of malignant gliomas: comparison of volumetric single arc technique (RapidArc), dynamic intensity-modulated technique and 3D conformal technique. *Radiat Oncol* 2009;93:593–6.
3. Lorentini S, Amelio D, Giri MG et al. IMRT or 3D-CRT in glioblastoma? A dosimetric criterion for patient selection. *Technol Cancer Res Treat* 2013;12:411–20.
4. MacDonald SM, Ahmad S, Kachris S et al. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. *J Appl Clin Med Phys* 2007;8:47–60.
5. Hermanto U, Frija EK, Lii MJ et al. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain? *Int J Radiat Oncol Biol Phys* 2007;67:1135–44.
6. Sakanaka K, Mizowaki T, Hiraoka M. Dosimetric advantage of intensity-modulated radiotherapy for whole ventricles in the treatment of localized intracranial germinoma. *Int J Radiat Oncol Biol Phys* 2012;82:e273–80.
7. Sakanaka K, Mizowaki T, Sato S et al. Volumetric-modulated arc therapy vs conventional fixed-field intensity-modulated radiotherapy in a whole-ventricular irradiation: a planning comparison study. *Med Dosim* 2013;38:204–8.
8. Niyazi M, Brada M, Chalmers AJ et al. ESTRO-ACROP guideline ‘target delineation of glioblastomas’. *Radiother Oncol* 2016;118:35–42.
9. Burman C, Kutcher GJ, Emami B et al. Fitting of normal tissue tolerance data to an analytic function. *Int J Radiat Oncol Biol Phys* 1991;21:123–35.
10. Choi B, Deasy JO. The generalized equivalent uniform dose function as a basis for intensity-modulated treatment planning. *Phys Med Biol* 2002;47:3579–89.
11. van’t Riet A, Mak AC, Moerland MA et al. A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate. *Int J Radiat Oncol Biol Phys* 1997;37:731–6.
12. Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. *Int J Radiat Oncol Biol Phys* 1991;21:109–22.
13. Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol* 2010;28:1963–72.
14. Youden WJ. Index for rating diagnostic tests. *Cancer* 1950;3:32–5.
15. Nguyen PL, Chen RC, Hoffman KE et al. Rectal dose–volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. *Int J Radiat Oncol Biol Phys* 2010;78:1081–5.
16. Chera BS, Fried D, Price A et al. Dosimetric predictors of patient-reported xerostomia and dysphagia with deintensiﬁed chemoradiotherapy for HPV-associated oropharyngeal squamous cell carcinoma. *Int J Radiat Oncol Biol Phys* 2017;98:1022–7.